Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sentinel lymph node biopsy (SLNB) is considered the most powerful prognostic indicator of survival in patients with cutaneous melanoma of intermediate thickness (1–4 mm). The use of SLNB in patients with melanoma with a tumour thickness >4.0 mm is still controversial. The purpose of the current study was to determine the prognostic value of SLNB in patients with thick cutaneous melanomas (tumour thickness >4.0 mm) in terms of progression-free survival (PFS) and overall survival (OS).
A retrospective single-centre study was performed at the Department of Dermatology and Allergy, University of Bonn, and the Department of Nuclear Medicine, University of Bonn, based on data collected between September 2000 and January 2010. A total of 142 patients with cutaneous melanoma of thickness >4.00 mm were identified, and 63 of these patients underwent SLNB.
Of the 63 patients in whom SLNB was performed, 25 (39.7 %) had a positive SLN. Ulceration was more frequent in SLN-positive patients (44 %) than in SLN-negative patients (18.4 %). The mean follow-up time for the 63 patients was 50.7 months. Positive SLN status predicted a significantly reduced life expectancy in the analyses of PFS and OS. In SLN-positive patients 5-year OS was 76 % and in SLN-negative patients was 84.2 % (p = 0.048). Patients with a combination of ulcerated tumour and positive SLN had the worst prognosis.
On the basis of our follow-up data, SLNB has to be recommended in patients with a tumour thickness >4.00 mm after exclusion of lymph node macrometastases or distant metastases. SLN status is the most significant prognostic factor in this group of patients.
- Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009;27:6199–206. CrossRef
- Ross MI. Sentinel node biopsy for melanoma: an update after two decades of experience. Semin Cutan Med Surg. 2010;29:238–48. CrossRef
- Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17. CrossRef
- Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15:670–3. CrossRef
- Vuylsteke RJ, van Leeuwen PA. Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long term follow-up results. J Clin Oncol. 2003;21:1057–65. CrossRef
- Hinz T, Ahmadzadehfar H, Wierzbicki A, Höller T, Wenzel J, Biersack HJ, et al. Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up. Eur J Nucl Med Mol Imaging. 2012;39:581–8 CrossRef
- Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003;49:567–88. CrossRef
- Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (≥ 4mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10:408–15. CrossRef
- Jacobs IA, Chang CK, Salti GI. Role of Sentinel lymph node biopsy in patients with thick (> 4mm) primary melanoma. Ann Surg. 2004;70:59–62.
- Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4mm) melanomas. J Dtsch Dermatol Ges. 2008;6:198–203. CrossRef
- Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137–41. CrossRef
- Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9:719–22. CrossRef
- Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implications of thick (≥4mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9:754–61.
- Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.
- Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK. Clinical node-negative thick melanoma. Arch Surg. 2002;137:291–5. CrossRef
- Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9. CrossRef
- Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8:400–14. CrossRef
- Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol. 2003;10:575–81. CrossRef
- Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305–17. CrossRef
- Topar G, Eisendle K, Zelger B, Fritsch P. Sentinel lymph node status in melanoma: a valuable prognostic factor? Br J Dermatol. 2006;154:1080–7. CrossRef
- Rondelli F, Vedovati MC, Becattini C, Tomassini GM, Messina S, Noya G, et al. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol Venereol. 2012;26:560–5. CrossRef
- Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: current practise and surgical controversies. Curr Probl Surg. 1994;31:253–74. CrossRef
- Kim SH, Garcia C, Rodriguez J, Coit DG. Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241–7. CrossRef
- Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role of lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥ 4mm) primary melanoma. Ann Surg Oncol. 2000;7:160–5. CrossRef
- Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001;44:762–6. CrossRef
- Singluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg. 1994;219:120–30. CrossRef
- Scoggins CR, Bowen AL, Martin 2nd RC, Edwards MJ, Reintgen DS, Ross MI, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145:622–7. CrossRef
- Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637–45. CrossRef
- Mandala M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45:2537–45. CrossRef
- Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (> 4mm) primary melanoma. Ann Surg Oncol. 1998;5:322–8. CrossRef
- Goeppner D, Ulrich J, Pokrywka A, Peters B, Gollnick H, Leverkus M. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4.0 mm. Dermatology. 2011;222:59–66. CrossRef
- Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9. CrossRef
- Miller MW, Vetto JT, Monroe MM, Weerasinghe R, Andersen PE, Gross N. False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg. 2011;145:606–11. CrossRef
- Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histological negative sentinel lymph nodes. Arch Surg. 1999;134:381–7. CrossRef
- Yudd AP, Kempf JS, Goydos JS, Stahl TJ, Feinstein RS. Use of sentinel node lymphoscintigraphy in malignant melanoma. Radiographics. 1999;19:343–53.
- Leong SP. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol. 2011;104:361–8.
- Pitman KT, Johnson JT, Brown ML, Myers EN. Sentinel lymph node biopsy in head and neck squamous cell carcinoma. Laryngoscope. 2002;112:2101–13. CrossRef
- Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin primary melanoma. Ann Surg Oncol. 2003;10:558–61. CrossRef
- Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG. The risk of regional lymph node metastases in patients with melanoma less than 1.0mm thick: recommendation for sentinel lymph node biopsy. J Am Coll Surg. 2003;197:403–7. CrossRef
- Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution
European Journal of Nuclear Medicine and Molecular Imaging
Volume 39, Issue 8 , pp 1316-1325
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- High-risk melanoma
- Sentinel lymph node biopsy
- Staging prognosis
- Industry Sectors
- Author Affiliations
- 1. Department of Dermatology and Allergology, Center of Integrated Oncology (CIO) Cologne Bonn University of Bonn, Bonn, Germany
- 2. Department of Nuclear medicine, University of Bonn, Bonn, Germany
- 3. Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany
- 4. Interdisciplinary Oncology Center (IOC) Munich, Nußbaumstr. 12, 80336, Munich, Germany